Ethinylestradiol sulfonate/norethisterone acetate

From Wikipedia, the free encyclopedia
Ethinylestradiol sulfonate /
norethisterone acetate
Ethinylestradiol sulfonate.svg
Norethisterone acetate.svg
Combination of
Ethinylestradiol sulfonateEstrogen
Norethisterone acetateProgestogen
Clinical data
Trade namesDeposiston
Other namesEES/NETA
Routes of
By mouth
Drug classEstrogen; Progestogen
CAS Number

Ethinylestradiol sulfonate/norethisterone acetate (EES/NETA), sold under the brand name Deposiston, is a combination medication of ethinylestradiol sulfonate (EES), an estrogen, and norethisterone acetate (NETA), a progestin, which was used as a combined birth control pill for women.[1] It was formulated as oral tablets and contained 1 mg EES and 5 mg NETA per tablet.[2][3][1] The medication had a long-lasting depot effect and was taken only once per week, for a total of four tablets per cycle.[1][2] It was developed and marketed by Jenapharm and was previously available in Germany.[2][1][3] EES/NETA was introduced for medical use in 1978.[1]

See also[edit]


  1. ^ a b c d e Schwarz S, Onken D, Schubert A (July 1999). "The steroid story of Jenapharm: from the late 1940s to the early 1970s". Steroids. 64 (7): 439–45. doi:10.1016/S0039-128X(99)00003-3. PMID 10443899. S2CID 40156824. 6.2. New estrogens. In 1967, Jenapharm, in conjunction with the Academy of Sciences (Kurt Ponsold, Gu¨nter Bruns, and Kurt Schubert in Jena and Hans Schick and Bernard Lu¨cke in Berlin), started a program of searching for new estrogens. [...] orally administered, strongly active estrogens with a depot effect. [...] the second objective was successfully attained. The rationale that an a-branched alkanesulfonic acid ester of ethinyl estradiol with a medium chain length should lead to a depot effect without the danger of active ingredient accumulation on longer usage [15] led in 1978 to the first once-a-week oral contraceptive (DEPOSISTONt), a combination of ethinylestradiol 3-isopropylsulfonate (17) and norethisterone acetate [16]. TURISTERONt, an estrogenic monotherapy with compound 17 that can still justify its position today [17], followed in 1980, as a therapy of prostate cancer. [...]
  2. ^ a b c Freimut A. Leidenberger (17 April 2013). Klinische Endokrinologie für Frauenärzte. Springer-Verlag. pp. 542–. ISBN 978-3-662-08110-5.
  3. ^ a b Muller (19 June 1998). European Drug Index: European Drug Registrations, Fourth Edition. CRC Press. pp. 338–. ISBN 978-3-7692-2114-5.